Data Sheet (Cat.No.T15004)

TargetMol

CP-532623

Chemical Properties



CAS No. : 261947-38-0

Formula: C27H27F9N2O3

Molecular Weight: 598.5

Storage: Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Actual storage temperature shall be subject to the COA.

Biological Description

Description	CP-532623, a close structural analog of Torcetrapib, is a CETP inhibitor with highly lipophilic properties. It elevates high-density lipoprotein cholesterol.
Targets(IC50)	CETP
In vitro	CP-532623 alters the kinetics of lymph lipid transport and decreases lymph lipid transport in chylomicrons. CP-532623 is highly lymphatically transported (28% of the dose). However, it lymphatic transport is closely correlated with drug affinity for ex-vivo lymph lipoproteins or triglyceride emulsions. But, it has poorly related to solubility in mixtures of lipoprotein core and/or surface lipids [2].
In vivo	CP-532623 (50 mg; p.o.; adult male greyhound dogs) treatment substantially transports into the lymphatic system (>25% dose) in fed and fasted dogs. Lymphatic triglyceride transport is significantly lower in fed dogs administered CP-532623. Food enhances oral bioavailability (from 44 to 58%, respectively) and the proportion of the absorbed dose transports via the lymph (from 61 to 86% and from 68 to 83%, respectively) [3].

Preparing Stock Solutions

	1mg	5mg	10mg
1 mM	1.6708 mL	8.3542 mL	16.7084 mL
5 mM	0.3342 mL	1.6708 mL	3.3417 mL
10 mM	0.1671 mL	0.8354 mL	1.6708 mL
50 mM	0.0334 mL	0.1671 mL	0.3342 mL

Please select the appropriate solvent to prepare the stock solution, according to the solubility of the product in different solvents. Please use it as soon as possible.

Note: The dilution table applies only to solid products. For liquid products, please calculate the stock solution based on the stated concentration and/or density.

Reference

Blasi E, et al. Effects of CP-532,623 and torcetrapib, cholesteryl ester transfer protein inhibitors, on arterial blood pressure. J Cardiovasc Pharmacol. 2009 Jun;53(6):507-16.

Trevaskis NL, et al. The mechanism of lymphatic access of two cholesteryl ester transfer protein inhibitors (CP524, 515 and CP532,623) and evaluation of their impact on lymph lipoprotein profiles. Pharm Res. 2010 Sep;27(9): 1949-64.

Trevaskis NL, et al. The role of the intestinal lymphatics in the absorption of two highly lipophilic cholesterol ester transfer protein inhibitors (CP524,515 and CP532,623). Pharm Res. 2010 May;27(5):878-93.

Tel:781-999-4286 E_mail:info@targetmol.com Address:34 Washington Street,Wellesley Hills,MA 02481